Avacta Advances Tumor-Targeted Oncology Pipeline and Extends Cash Runway Into Q3 2026

Avacta Group plc ( (GB:AVCT) ) has provided an announcement.

Avacta reported strong operational and R&D progress in 2025, highlighting encouraging efficacy and safety data from its faridoxorubicin (AVA6000) Phase 1b expansion cohorts in salivary gland cancer and continued enrollment to refine trial design for later-stage studies. The company advanced its second pre|CISION® program, FAP-Exd (AVA6103), with supportive pharmacology data, a Phase 1 trial set to start in early 2026 across multiple U.S. specialty oncology centers in four AI-selected tumor types, and the introduction of new platform innovations including a sustained-release mechanism and a dual-payload delivery technology. Financially, Avacta raised £22.5m in equity during 2025 and ended the year with £16.9m in cash and equivalents, providing funding into the third quarter of 2026 to reach key data readouts for both AVA6000 and AVA6103 while it continues active partnering discussions that could shape the design, funding and risk profile of its subsequent pivotal trials and broader pipeline development.

The most recent analyst rating on (GB:AVCT) stock is a Hold with a £53.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.

Spark’s Take on GB:AVCT Stock

According to Spark, TipRanks’ AI Analyst, GB:AVCT is a Neutral.

Avacta Group plc’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While there is some progress in clinical programs, financial constraints and lack of partnerships remain significant risks. The stock’s valuation is unattractive due to negative earnings and no dividend yield.

To see Spark’s full report on GB:AVCT stock, click here.

More about Avacta Group plc

Avacta Group plc is a clinical-stage biopharmaceutical company focused on oncology, developing its proprietary pre|CISION® tumor-activated drug delivery platform. The company’s lead programs, faridoxorubicin (AVA6000) and FAP-Exd (AVA6103), aim to deliver chemotherapy agents directly into tumors at high concentrations while limiting systemic toxicity, targeting difficult-to-treat solid cancers such as salivary gland, pancreatic, gastric, small cell lung and cervical cancers. Avacta’s strategy centers on advancing this platform, expanding its intellectual property estate, and engaging with global pharmaceutical partners to support late-stage development and commercialization.

Average Trading Volume: 2,750,046

Technical Sentiment Signal: Sell

Current Market Cap: £238.4M

See more insights into AVCT stock on TipRanks’ Stock Analysis page.